10:36 Roth Capital says deal worth $12/share or more
May 8, 2013
10:36 EDT ALXA
theflyonthewall: Alexza deal with Teva could be worth $12 per share or more, says Roth Capital
After Teva (TEVA) agreed to market Alexza's (ALXA) Adasuve - an acute treatment of agitation associated with schizophrenia or bipolar disorder - in the U.S., Roth Capital thinks the deal could be worth about $12 per share or more to Alexza. The firm thinks the deal has several positive aspects for Alexza, including a $40M upfront cash payment, a reduction of risk, and validation of the drug. The firm keeps a Buy rating on the stock.